Prévisions

Aucune donnée d'analyste n'est disponible pour cette entreprise.

Actualités Accéder au fil d'actualités

Stada buys 16 Orifarm brands for vitamins and dietary supplements

Stada acquires 16 brands for vitamins, minerals and dietary supplements from Orifarm to strengthen its presence with consumers and pharmacies in the Nordic countries, Belgium and Poland. The takeover is the first acquisition under new majority owner CapVest Partners; CEO Peter Goldschmidt announces further acquisitions. A small number of Orifarm employees will transfer to Stada, and the purchase price was not disclosed. » Plus sur manager-magazin.de
Stada boosts 2025 revenue and earnings thanks to specialty medicines

Stada raised adjusted revenue at constant exchange rates in 2025 by six percent to €4.3 billion, driven by strong growth in specialty medicines. Revenue of the specialty division exceeded €1 billion, and adjusted EBITDA rose eight percent to €961 million. The company plans to expand its online business, is considering worldwide acquisitions, and aims to grow its brand portfolio in fast‑growing categories. » Plus sur finanzen.net
Stada sale to Capvest shapes record year for M&A in Germany

The sale of Stada for $11.7 billion to a consortium led by Capvest was the largest acquisition in Germany in 2025; Bain Capital and Cinven retain a minority stake. Overall, by mid-December 1,641 German firms were sold for $107.1 billion, and total M&A volume in Germany rose to $167.5 billion (up 17% versus 2024). Financial investors invested a record $49.9 billion and were behind four of the five largest transactions, while the number of deals fell to 2,464 — the lowest level since 2020. » Plus sur capital.de